Glycated hemoglobin measurement and prediction of cardiovascular disease.

DOI: http://doi.org/10.1001/jama.2014.1873 Journal: JAMA E-pub date: 26 Mar 2014 Authors: Emerging Risk Factors Collaboration, E Di Angelantonio, P Gao, H Khan, AS Butterworth, D Wormser, S Kaptoge, SR Kondapally Seshasai, A Thompson, N Sarwar, P Willeit, PM Ridker, ELM Barr, K-T Khaw, BM Psaty, H Brenner, B Balkau, JM Dekker, DA Lawlor, M Daimon, J Willeit, I Njølstad, A Nissinen, EJ Brunner, LH Kuller, JF Price, J Sundström, MW Knuiman, EJM Feskens, WMM Verschuren, N Wald, SJL Bakker, PH Whincup, I Ford, U Goldbourt, A Gómez-de-la-Cámara, J Gallacher, LA Simons, A Rosengren, SE Sutherland, C Björkelund, DG Blazer, S Wassertheil-Smoller, A Onat, A Marín Ibañez, E Casiglia, JW Jukema, LM Simpson, S Giampaoli, BG Nordestgaard, R Selmer, P Wennberg, J Kauhanen, JT Salonen, R Dankner, E Barrett-Connor, M Kavousi, V Gudnason, D Evans, RB Wallace, M Cushman, RB D'Agostino, JG Umans, Y Kiyohara, H Nakagawa, S Sato, RF Gillum, AR Folsom, YT van der Schouw, KG Moons, SJ Griffin, N Sattar, NJ Wareham, E Selvin, SG Thompson, J Danesh

Glycated hemoglobin measurement and prediction of cardiovascular disease.

Abstract:

IMPORTANCE: The value of measuring levels of glycated hemoglobin (HbA1c) for the prediction of first cardiovascular events is uncertain. OBJECTIVE: To determine whether adding information on HbA1c values to conventional cardiovascular risk factors is associated with improvement in prediction of cardiovascular disease (CVD) risk. DESIGN, SETTING, AND PARTICIPANTS: Analysis of individual-participant data available from 73 prospective studies involving 294,998 participants without a known history of diabetes mellitus or CVD at the baseline assessment. MAIN OUTCOMES AND MEASURES: Measures of risk discrimination for CVD outcomes (eg, C-index) and reclassification (eg, net reclassification improvement) of participants across predicted 10-year risk categories of low (